Assessment of F/HN-Pseudotyped Lentivirus as a Clinically Relevant Vector for Lung Gene Therapy

Citation for published version:

Digital Object Identifier (DOI):
10.1164/rccm.201206-1056OC

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
American Journal of Respiratory and Critical Care Medicine

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Assessment of F/HN-Pseudotyped Lentivirus as a Clinically Relevant Vector for Lung Gene Therapy

Uta Griesenbach1,2, Makoto Inoue3, Cuixiang Meng1,2, Raymond Farley1,2, Mario Chan1,2, Nikki K. Newman1,2, Andrea Brun1,2, Jun You3, Angela Kerton4, Angela Shoemark5, A. Christopher Boyd2,6, Jane C. Davies1,2, Tracy E. Higgins1,2, Deborah R. Gill2,7, Stephen C. Hyde2,7, J. Alastair Innes2,6, David J. Porteous2,6, Mamoru Hasegawa3, and Eric W. F. W. Alton1,2

1Department of Gene Therapy and 4Central Biomedical Services, Imperial College London, London, United Kingdom; 2The United Kingdom Cystic Fibrosis Gene Therapy Consortium, London, United Kingdom; 3DNAVEC Corporation, Tsukuba, Japan; 4Paediatric Department, Royal Brompton Hospital, London, United Kingdom; 5Medical Genetics Section, Centre for Molecular Medicine, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom; and 6Gene Medicine Group, Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom

Rationale: Ongoing efforts to improve pulmonary gene transfer thereby enabling gene therapy for the treatment of lung diseases, such as cystic fibrosis (CF), has led to the assessment of a lentiviral vector (simian immunodeficiency virus [SIV]) pseudotyped with the Sendai virus envelope proteins F and HN. Objectives: To place this vector onto a translational pathway to the clinic by addressing some key milestones that have to be achieved. Methods: F/HN-SIV transduction efficiency, duration of expression, and toxicity were assessed in mice. In addition, F/HN-SIV was assessed in differentiated human air–liquid interface cultures, primary human nasal epithelial cells, and human and sheep lung slices. Measurements and Main Results: A single dose produces lung expression for the lifetime of the mouse (~2 yr). Only brief contact time is needed to achieve transduction. Repeated daily administration leads to a dose-related increase in gene expression. Repeated monthly administration to mouse lower airways is feasible without loss of gene expression. There is no evidence of chronic toxicity during a 2-year study period. F/HN-SIV leads to persistent gene expression in human differentiated airway cultures and human lung slices and transduces freshly obtained primary human airway epithelial cells. Conclusions: The data support F/HN-pseudotyped SIV as a promising vector for pulmonary gene therapy for several diseases including CF. We are now undertaking the necessary refinements to progress this vector into clinical trials.

Keywords: lentivirus; cystic fibrosis; gene therapy; lung; gene transfer

Gene transfer to the airway epithelium has been more difficult than originally anticipated, largely because of significant extracellular and intracellular barriers in the lung (1). In general, viral vectors are more adapted to overcoming these barriers than nonviral gene transfer agents. Viral vectors that have a natural tropism for the airway epithelium, such as those derived from adenovirus, aden-associated virus, and Sendai virus (SeV), have been evaluated for cystic fibrosis (CF) gene therapy. SeV vector, in particular, leads to log orders higher gene expression than nonviral formulation when applied to the apical surface of airway epithelial cells (2, 3). However, gene expression is transient and repeated administration is inefficient (4, 5). These vectors are, therefore, unlikely to solve the challenge of life-long gene therapy treatment for CF.

Lentiviral vectors are commonly pseudotyped with the G glycoprotein from the vesicular stomatitis virus (VSV-G) allowing for a broad tissue tropism. However, VSV–G–pseudotyped vectors are comparatively inefficient at transducing airway epithelial cells and require the addition of tight junction openers, such as lysophosphatidylcholine, to allow virus entry into airway cells (6, 7). Several groups have attempted to further improve lentiviral vector uptake into airway epithelium by changing the viral envelope proteins. Glycoproteins from Ebola or Marburg virus that naturally transfect airway epithelial cells by the apical membrane showed early promise (8), but have more recently been superseded by viral vectors pseudotyped with the influenza M2 envelope glycoprotein (9), baculovirus protein GP64 (10), or the SeV-derived F and HN envelope proteins (11, 12).

The F/HN-pseudotyped simian immunodeficiency virus vector (F/HN-SIV) transduces rodent airway epithelial cells in vitro (12). Recently, we have shown that F/HN-SIV leads to persistent expression in the mouse nose (>1 yr) importantly allowing for monthly repeat administration without significant loss of efficacy (11). It is currently unclear whether the prolonged expression is caused by vector integration into pulmonary stem or progenitor cells, or by the long life-span of airway epithelial cells, which as recently reported may have a half-life of up to 17 months (13). It is also unclear how on repeated administration

AT A GLANCE COMMENTARY

Scientific Knowledge on the Subject

Gene transfer to the airway epithelium is more difficult than originally anticipated. Until now viral gene transfer agents have not been useful for the treatment of chronic lung disease, such cystic fibrosis (CF), because of immunogenicity, which prevents successful repeat administration. Lentivirus-based vectors are a notable exception.

What This Study Adds to the Field

Moving novel therapies to the clinic requires that relevant evidence for safety and efficacy is gathered in appropriate models. Here, we provide a body of supportive evidence for F/HN-pseudotyped simian immunodeficiency virus as a potential gene transfer agent for CF including lifetime gene expression and efficient repeat administration in mouse lung, lack of chronic toxicity, and persistent gene expression in human ex vivo models.
the viral vector evades the immune system, although interestingly liposomes that contain SeV proteins (HJV-liposome) can also be repeatedly administered (14). This feature, and the efficient and prolonged expression profile and the ability to administer through the apical surface of the respiratory epithelium without preconditioning, makes the vector an attractive candidate for treating CF, which is a chronic disease and requires lifelong correction of the genetic defect in airway epithelial cells.

Here, we have further developed the F and HN–seudotyped SIV toward clinical evaluation. We show that repeated administration to the mouse lower airways is feasible. We also confirm the long-term safety profile of this viral vector and show that it transduces the relevant human airway epithelial cells required for CF gene therapy.

METHODS

Viral Vector Production

Purified and concentrated F/HN-SIV expressing firefly luciferase (F/HN-SIV-Lux) or enhanced green fluorescent protein (F/HN-SIV-GFP) under the transcriptional control of the cytomegalovirus (CMV) enhancer/promoter were prepared and titrated as previously described (11) (see online supplement for further details).

Mouse Lung Transfection

Female C57BL/6N mice (6–8 wk old) were used (see online supplement). A 100-μl viral vector in Dulbecco’s phosphate-buffered saline (D-PBS) was administered to the mouse nose and “sniffed” into the lung as previously described (15) (see RESULTS and FIGURES for details about vector titers used) and gene expression quantified (see online supplement).

For the daily repeat administration experiments, groups of mice were treated over 10 days with either nine daily doses of D-PBS followed by a single dose of F/HN-SIV-Lux, five daily doses of D-PBS followed by five daily doses of F/HN-SIV-Lux, or 10 daily doses of F/HN-SIV-Lux. Gene expression was analyzed 28 days after the final F/HN-SIV-Lux administration.

For the monthly repeat administration experiments groups of mice were transduced with either one dose of F/HN-SIV-Lux (single-dose group), or two doses of F/HN-SIV-GFP (Day 0, Day 28), followed by F/HN-SIV-Lux on Day 56 (repeat-dose group). Importantly, mice receiving F/HN-SIV-Lux (single-dose group) and F/HN-SIV-Lux on Day 56 (repeat-dose group) were of similar age and were transduced at the same time. Gene expression was analyzed 28 days after F/HN-SIV-Lux administration.

Toxicology

Over the 24-month study period mice were carefully observed daily and were given a full clinical examination every 2 weeks (including palpation of the abdomen for tumors) by an experienced animal technician, and bodyweight was recorded. Histologic assessment was performed in mice that showed signs of illness throughout the study period. In addition, lungs from asymptomatic mice culled at the end of the 24-month study period were also analyzed (see online supplement).

Histologic Assessment of GFP Expression

Mouse lungs were transduced with F/HN-SIV-GFP (10^8 TU/mouse in 100 μl) by nasal sniffing. Animals receiving D-PBS only were used as negative controls (n = 4 per group). One month after transduction animals were culled and GFP expression was assessed in lung tissue (see online supplement).

Gene Transfer into Relevant Preclinical Model

Gene transfer into human air–liquid interface (ALI) cultures, human nasal brushings, and lung slices was performed as described in the online supplement.

Statistical Analysis

Analysis of variance followed by a Bonferroni post hoc test or Kruskal-Wallis test followed by Dunn multiple comparison post hoc test was performed for multiple group comparison after assessing parametric and nonparametric data distribution with the Kolmogorov-Smirnov normality test, respectively. An independent Student t test or a Mann-Whitney test was performed for two-group parametric and nonparametric data as appropriate. Pearson correlation was performed for parametric data. All analyses were performed using GraphPad Prism 4 (GraphPad Software, Inc., La Jolla, CA) and the null hypothesis was rejected at P less than 0.05.

RESULTS

Gene Expression in Mouse Lung Persists and Is Stable

We first assessed if F/HN-SIV produced measurable levels of luciferase in murine lower airways (lungs), and if this expression was dose-related. Mice were transduced with F/HN-SIV-Lux (10^7 or 10^8 TU/mouse in 100 μl total volume) by nasal sniffing (n = 8 per group) or received D-PBS (n = 8). Two days after transduction mice were culled and luciferase expression quantified in lung homogenates. Luciferase expression was detectable and dose-related (10^7 TU/mouse, 2 ± 0.3 relative light units [RLU]/mg protein; 10^8 TU/mouse, 27 ± 6.4 RLU/mg protein, P < 0.01; D-PBS, 0.01 ± 0.03 RLU/mg). However, gene expression was also production batch-related (see online supplement).

We next assessed if expression in mouse lungs persisted. Mice were transduced with F/HN-SIV-Lux (5 × 10^7 TU/mouse in 100 μl total volume) by nasal sniffing (n = 8 in two independent experiments) or received D-PBS (negative controls, n = 6) and luciferase expression was quantified using in vivo bioluminescence imaging (BLI) at regular intervals for up to 22 months. Luciferase-mediated photon emission was detectable in all treated mice 2 months after transduction (SIV, 362,660 ± 63,922 photons/s/cm^2; n = 8; D-PBS, 66,535 ± 4,868 photons/s/cm^2; n = 6; P < 0.005). Seven out of eight mice survived for 16 months and four out of the eight mice survived until termination of the experiment at 22 months. All of the SIV transduced mice had detectable luciferase expression at all time points. Photon emission increased modestly, but significantly (P < 0.005), over time (SIV at 2 mo, 381,123 ± 70,665 photons/s/cm^2; at 16 months, 543,156 ± 65,234 photons/s/cm^2; n = 7 mice with data for both time-points). This was maintained at 22 months (2 mo, 367,485 ± 115,923 photons/s/cm^2; 22 months, 1,407,000 ± 435,790 photons/s/cm^2; n = 4 mice with data for both time-points). In contrast, photon emission in D-PBS–treated mice remained stable over the same time period (Figures 1A and 1B).

An increase in photon emission may indicate an increase in luciferase expression potentially caused by an increase in the number of luciferase-expressing cells over time or may be a peculiarity of BLI. We therefore repeated the experiment comparing BLI with post-mortem quantification of luciferase expression in lung tissue homogenates in the same animals. Mice were transduced with F/HN-SIV (10^7 TU/mouse, n = 8–12 per time-point) and at regular intervals over a 24-month period (for technical reasons BLI could only be performed between 6 and 24 months after gene transfer) and post-mortem quantification of luciferase expression in lung tissue homogenate was performed in cohorts of mice. Similar to results described previously photon emission significantly (P < 0.001) increased over the study period (BLI at 6 mo, 87,915 ± 8,871 photons/s/cm^2; BLI at 24 mo, 310,334 ± 36,274 photons/s/cm^2) (Figure 1C), whereas detectable levels of luciferase in tissue homogenate remained stable (Figure 1D). There was no correlation between in vivo photon emission and luciferase expression quantified in tissue homogenates (Spearman r = 0.205; P = 0.11; n = 63 paired data points from 6–24 mo). However, luciferase expression quantified in tissue homogenates correlated well with photon emission from the same animal when lungs were extracted before BLI (Figure 1E) (Spearman r = 0.75; P = 0.01; n = 11 paired data points at 24 mo), which implies that photon quenching may occur in vivo.
Additional technical considerations relating to limitations of BLI and virus batch-to-batch variability became apparent in this study (see online supplement).

To determine what cell types were transduced in the lung we transfected mice with F/HN-SIV-GFP (10^8 TU/mouse) or D-PBS (n = 4 per group) by nasal sniffing and assessed GFP expression 1 month after transduction. GFP expression was detectable in airway epithelial cells, and also in the alveolar region (Figure 1F).

**F/HN-SIV Requires Only Short Contact Time to Achieve Efficient Transduction**

We compared prolonged contact time of the vector with the nasal epithelium (by perfusion) with very brief contact time (sniffing). The latter led to equally efficient transduction of the nasal epithelium as the former (Figures 2A and 2B). This suggests that a short contact time between the viral vector and the target cell may be sufficient for efficient vector uptake into the cells, of potential importance in future clinical trials.

Gene expression in the nose also persisted for 15–22 months in seven out of eight mice, but in contrast to the lung gradually declined by approximately 60% over this period (SIV Month 2, 1,509,000 ± 316,612 photons/s/cm²; SIV Month 15, 583,951 ± 228,804 photons/s/cm², P < 0.05, n = 7 per group; D-PBS Month 15, 53,021 ± 2,325 photons/s/cm², P < 0.005), which may be caused by different cell types being transduced in nose and lung or different turnover rates of the cells at these two sites. Consistent with our previous data using nonviral gene transfer agents (16), intranasal administration of luciferin (the substrate for luciferase) boosted F/HN-SIV-Lux–derived photon emission in mice that were negative after intraperitoneal administration of luciferin (Figure 2C).

**Daily Repeat Administration to the Lung Is Feasible**

Although gene expression after a single dose of F/HN-SIV persists for the lifetime of the animal, a single dose may not be sufficient to achieve therapeutic benefit in humans. It is, for example, conceivable that the total volume required for delivery of the optimal vector titer to the human lung may be too large for a single dose and administration may have to be split into several doses to accommodate the volume. We, therefore, assessed if repeated daily administration of F/HN-SIV-GFP was feasible.
administration of the viral vector is feasible and if this leads to incrementally increased gene expression compared with a single dose. Mice (n = 8 per group) were treated with either F/HN-SIV-Lux daily for 10 days (10^6 TU/day in 100 μl) or with PBS (100 μl) for 5 days followed by 5 days of F/HN-SIV-Lux (10^6 TU/day) or with D-PBS for 9 days followed by 1 day of F/HN-SIV-Lux (10^6 TU/day); Lux expression was quantified 28 days after the last dose. Gene expression was significantly correlated (Pearson r^2 = 0.61; P < 0.0001) with the number of F/HN-SIV-Lux doses given (Figure 3A) and indicated that daily repeat
administration is feasible and significantly increases transduction efficiency.

**Monthly Repeat Administration to the Lung Is Feasible**

Although a single dose of F/HN-SIV generates persistent gene expression for approximately 2 years in mice (lifetime of the animal), a single dose is unlikely sufficient to achieve clinical benefit for the lifetime of a patient with CF. Therefore, a crucial question is whether the vector can produce gene expression on repeated administration to the lung. As shown previously, daily administration was feasible, but this timeframe is unlikely to be sufficient for the development of effective immune responses to the viral vector.

---

**Figure 2.** F/HN simian immunodeficiency virus (SIV) requires only short contact time to achieve efficient transduction. Luciferase (Lux) expression was compared in mice receiving F/HN-SIV-Lux ($3 \times 4 \times 10^8$ TU/mouse in 100 µl) by slow perfusion (1.3 µl/min, $n = 10$) or as bolus administration by nasal sniffing ($n = 8$). (A) Bioluminescence in vivo signal in the mouse nose. Representative images of three mice are shown. (B) Quantification of in vivo bioluminescence in mouse nose after slow perfusion or nasal sniffing of the vector. Each dot represents one animal. Horizontal bars represent the group median. (C) Bioluminescence in vivo signal in mouse nose after intraperitoneal (IP) or intranasal (IN) administration of luciferin. Representative images of two of five mice are shown. Lux expression after slow perfusion of the F/HN-SIV-Lux has been published previously (11).
We therefore conducted repeat administration experiments at monthly dosing intervals, a period we have shown to be sufficient because they showed signs of illness or were found dead during the study. Histologic examination revealed a range of pathology commonly found in aging C57BL/6N mice equally distributed between the two groups (Table 2).

**Figure 3.** Daily and monthly repeat administration to the lung is feasible. (A) Daily readministration. Mice \((n = 8\) per group) were treated with either F/HN simian immunodeficiency virus (SIV) luciferase (Lux) for 10 days \((10^6 \text{ TU/day})\) or with D phosphate buffered saline (PBS) for 5 days followed by 5 days of F/HN-SIV-Lux \((10^6 \text{ TU/day})\) or with D-PBS for 9 days followed by 1 day of F/HN-SIV-Lux \((10^6 \text{ TU})\). Lux expression was analyzed 28 days after F/HN-SIV-Lux administration. (B) Monthly readministration. Mice were either treated with one dose of F/HN-SIV-Lux (single-dose group) or two doses of F/HN-SIV-GFP \((\text{Day 0, Day 28})\), followed by F/HN-SIV-Lux on Day 56 (repeat-dose group). All mice receive \(10^6 \text{ TU/dose} \quad (n = 20 \text{ per group})\) and gene expression was analyzed 28 days after F/HN-SIV-Lux administration. Each dot represents one animal. Horizontal bars represent the group median. Dotted line represents negative control values, \(***P < 0.0001\) when compared with 5 and 10 doses, \(**P < 0.01\) when compared with 10 doses. RLU = relative light units.

**F/HN-SIV Transduction of Human Ex Vivo Models Is Feasible**

**F/HN-SIV achieves persistent gene expression in differentiated human ALI cultures.** To assess the efficiency of the viral vector in relevant human tissues we transduced human ALIs with F/HN-SIV-Lux at multiplicity of infection (MOI) 25 or 250 \((n = 5 \text{ per group})\), with D-PBS control \((n = 3)\), or with GL67A, the most efficient nonviral gene transfer agent for airway epithelium. The latter was complexed with a eukaryotic expression plasmid expressing luciferase \((10 \mu \text{g } \text{pCIKLux per ALI equivalent to } 3 \times 10^{12} \text{ plasmids and an approximate MOI of } 7 \times 10^9) \quad (n = 3)\) and luciferase expression followed using BLI for 3 months (representative images are shown in Figure 5A). F/HN-SIV–mediated expression was dose-related and persisted for at least 3 months without the loss of activity. In contrast, transfection with GL67A/pCIKLux was only barely detectable at an early time-point (Day 2) after transfection (Figure 5B). Lipid-mediated gene transfer was associated with cell damage as indicated by the appearance of small holes in the ALIs; this was not seen with exposure of the ALIs to the lentiviral vector (data not shown).

**F/HN-SIV transduces primary human pulmonary cells.** We assessed if F/HN-SIV transduces primary human airway epithelial cells obtained from nasal brushings or human lung slices generated from lung resection tissue (Figure 6A). Nasal brushings were transduced with F/HN-SIV-Lux at an MOI of 25 and 250 or treated with D-PBS \((n = 6 \text{ per group})\) and luciferase expression was quantified 24 hours after transduction (cell viability precludes longer time scales). Luciferase expression was significantly \((P < 0.005)\) increased compared with PBS control subjects (Figure 6B). These results were confirmed in an independent experiment \((\text{MOI 25, } 9.7 \times 10^6 \pm 0.9 \times 10^6; \text{MOI 250, } 1.5 \times 10^7 \pm 1.6 \times 10^7; \text{negative control subjects, } 2.762 \pm 241 \text{RLU/mg protein}, n = 4 \text{ per group})\).

**F/HN-SIV achieves persistent gene expression in human and sheep lung slices.** Precision-cut human lung slices were transduced with F/HN-SIV-Lux \((2 \times 10^7 \text{ TU/slice})\), or remained untransduced, and luciferase expression quantified for 14 days after transduction. Assessment of later time-points is currently not feasible because of limited tissue viability (Figure 6C). Two independent experiments were performed (see open and closed symbols in the figure) but data were pooled to allow for robust statistical analysis. Significant \((P < 0.001)\) and stable gene expression was detectable for at least 14 days \((P < 0.05)\) after gene transfer.

We also repeated these experiments in sheep lung slices (two independent experiments), which generally survive longer than human lung slices when cultured (unpublished data). Significant \((P < 0.001 \text{ to } P < 0.05)\) and stable luciferase expression was detectable at all time-points for at least 26 days after transduction.
These results indicate that F/HN–SIV is able to transduce primary human and sheep pulmonary cells and provides persistent expression.

**DISCUSSION**

The efforts of one of our team to improve pulmonary gene transfer and enable gene therapy for the treatment of lung diseases, such as CF, have led to the development of a lentiviral vector pseudotyped with the SeV envelope proteins F and HN (12). Moving novel therapies to the clinic requires that relevant evidence for safety and efficacy is gathered in appropriate models. Here, we begin to place this vector onto a translational pathway to the clinic and provide a body of supportive evidence for F/HN-pseudotyped SIV as a potential gene transfer agent for CF. We show that (1) a single dose produces lung expression for the life-time of the mouse (~2 yr); (2) only brief contact time (seconds) is needed to achieve transduction; (3) repeated daily administration leads to a dose-related increase in gene expression; (4) repeated monthly administration to mouse lower airways is feasible without loss of gene expression; (5) there is no evidence of chronic toxicity during a 2-year study period; and (6) F/HN-SIV transduction generates persistent gene expression in human differentiated airway cultures and freshly obtained human lung slices and transduces freshly obtained primary human airway epithelial cells.

At least two previous studies have shown that lentiviral vector–mediated transduction of mouse lung leads to persistent (15 and 24 mo) gene expression in the murine lower airways (18, 19). However, both studies used a VSV-G–pseudotyped lentiviral vector, which almost exclusively transduces alveolar macrophages, rather than lung epithelial cells. In addition to the airway epithelium, the target for CF gene therapy, cells in the peripheral lung (a mixture of pneumocytes and macrophages) are transduced after bolus administration of the viral vector by nasal sniffing, which may lead to pooling of liquid in the

**TABLE 1. MOUSE WEIGHTS 6, 15, AND 24 MONTHS AFTER LUNG TRANSDUCTION WITH F/HN-SIV-LUX OR PBS ADMINISTRATION**

<table>
<thead>
<tr>
<th>Months After Treatment</th>
<th>PBS-treated Mice 8 g</th>
<th>SIV-treated Mice 8 g</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>24.9 (0.5) n = 48</td>
<td>25.4 (0.3) n = 71</td>
</tr>
<tr>
<td>15</td>
<td>30.7 (0.7) n = 47</td>
<td>31.4 (0.8) n = 35</td>
</tr>
<tr>
<td>24</td>
<td>30.1 (1.4) n = 36</td>
<td>29.3 (1.1) n = 12</td>
</tr>
</tbody>
</table>

*Definition of abbreviations: LUX = luciferase; PBS = phosphate-buffered saline; SIV = simian immunodeficiency virus.*

Mean weights (± SEM) are shown. There were no differences between PBS- and SIV-treated mice.
peripheral lung. To determine transduction efficiency of airway epithelium more accurately the viral vector needs to be administered by nebulization. Further work is now warranted to determine whether F/HN-SIV is stable in clinically approved nebulizers and that virus production can be scaled up to the extent required for clinical studies. We are currently assessing if F/HN-SIV is stable in clinically approved nebulizers and preliminary results indicate that infectivity after nebulization is retained (data not shown); and scaling up vector production to allow us to move into in vivo nebulization experiments in the near future.

Although expression levels in the lung are completely stable over the 2-year study period, those in the nasal epithelium declined by approximately 60%. The latter is consistent with our previous data (11) and may relate to different cell types being transduced in the lung (airway epithelium and alveolar cells) and nose (mainly ciliated airway epithelial cells) (11) and different turnover rates of these cells at these two sites. Although, we do not have information about turnover of nasal airway epithelium, Rawlins and Hogan (13) have shown that the half-life of ciliated airway epithelial cells in the mouse trachea and lung differs (trachea, average half-life 6 mo; lung, average half-life 17 mo).

We have previously shown that prolongation of contact time between nonviral gene transfer agents and the airway epithelium significantly increases gene expression (20). In our previous study, we therefore slowly perfused F/HN-SIV (1.3 $\mu$l/min) onto the mouse nasal epithelium to maximize transduction (11). Transduction efficiency in the nasal epithelium after administration of a bolus of fluid that is rapidly (seconds) sniffed into the lung led to similar levels of photon emission. This implies that brief contact time between F/HN-SIV and the target cell may be sufficient for efficient vector uptake into the cells, which is an important factor for clinical translation. F/HN-SIV therefore mimics SeV (2) from which the F and HN envelope proteins were derived.

We and others have previously shown that repeated administration of lentiviral vectors to the mouse nasal epithelium is feasible (10, 11). To move our translational research a step closer to clinical relevance we now assessed repeat administration of the vector in the lung. Two types of repeat administration experiments were performed: daily and monthly. The former was assessed because it is conceivable that the total volume required for delivery of a specific vector titer to the human lung may be too large for a single dose and administration may have to be

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Death (mo after treatment)</th>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS</td>
<td>15</td>
<td>Found dead</td>
</tr>
<tr>
<td>PBS</td>
<td>18</td>
<td>Lymphoma</td>
</tr>
<tr>
<td>PBS</td>
<td>19</td>
<td>Lymphoma</td>
</tr>
<tr>
<td>PBS</td>
<td>20</td>
<td>Lymphoma</td>
</tr>
<tr>
<td>PBS</td>
<td>20</td>
<td>Inconclusive</td>
</tr>
<tr>
<td>PBS</td>
<td>21</td>
<td>No pathology found</td>
</tr>
<tr>
<td>PBS</td>
<td>21</td>
<td>Lymphoma</td>
</tr>
<tr>
<td>PBS</td>
<td>23</td>
<td>No pathology found</td>
</tr>
<tr>
<td>PBS</td>
<td>23</td>
<td>Found dead</td>
</tr>
<tr>
<td>PBS</td>
<td>23</td>
<td>Lymphoma</td>
</tr>
<tr>
<td>PBS</td>
<td>24</td>
<td>Found dead</td>
</tr>
<tr>
<td>SIV</td>
<td>3</td>
<td>Peritonitis</td>
</tr>
<tr>
<td>SIV</td>
<td>13</td>
<td>Found dead</td>
</tr>
<tr>
<td>SIV</td>
<td>17</td>
<td>Found dead</td>
</tr>
<tr>
<td>SIV</td>
<td>19</td>
<td>Pancreatic tumor</td>
</tr>
<tr>
<td>SIV</td>
<td>21</td>
<td>Multiorgan inflammation</td>
</tr>
<tr>
<td>SIV</td>
<td>24</td>
<td>Found dead</td>
</tr>
<tr>
<td>SIV</td>
<td>24</td>
<td>Multifocal lymphocytic inflammation</td>
</tr>
</tbody>
</table>

**TABLE 2. CAUSE OF MORTALITY OF PBS- AND F/HN-SIV–TREATED MICE OVER A 24-MONTH PERIOD**

**Definition of abbreviations:** PBS = phosphate-buffered saline; SIV = simian immunodeficiency virus.

---

**Figure 5.** Persistent gene expression in differentiated air–liquid interface (ALI) cultures. Differentiated human ALI cultures were transduced with F/HN simian immunodeficiency virus (SIV) luciferase (Lux) at multiplicity of infection (MOI) 25 or 250 (n = 5 per group), transfected with GL67A complexed to a eukaryotic expression plasmid expressing Lux (10 $\mu$g pCIKLux per ALI equivalent to $3 \times 10^{12}$ plasmids and an approximate MOI of $7 \times 10^6$) (n = 3) or treated with phosphate-buffered saline (PBS) (negative control, n = 3). Lux expression was followed using bioluminescence imaging for 3 months. (A) Representative images are shown. (B) Quantification of Lux expression over 3 months.
split into several doses to accommodate the volume. Here, we show that daily repeat administration is feasible and leads to a dose-related increase in gene expression. Although important, we have not yet addressed the question if “split-dose” delivery of a specific vector titer (e.g., 10 doses of $10^7$ TU) offers advantages over “single-dose” delivery of the same vector titer (e.g., one dose of $10^8$ TU), which may also be a relevant translational research question. Although efficient daily-repeat administration is encouraging, this time-frame is generally not considered to be sufficient to induce robust immune responses to the viral vector. To confirm that long-term F/HN-SIV repeat administration to the lower airways is feasible viral vector was administered monthly over a 3-month period. This dosing interval may be of clinical relevance and is also an accepted timeframe for the induction of robust immune responses. Uniquely for a viral vector (in our hands), luciferase expression levels after one and three doses were identical and more than 4 log orders higher than in untransduced control mice.

Another important consideration for translational development of a gene transfer agent is safety. The occurrence of leukemia and myelodysplasia in some patients with primary immunodeficiencies after treatment with $\gamma$ retroviral vector-transduced bone marrow (21) raises concerns about the safety of integrating viral vectors. The risk of insertional mutagenesis in slowly turning over differentiated lung epithelium is unknown, but is likely to be lower than in rapidly dividing bone marrow cells. In addition, the improved design of self-inactivating lentiviral vectors has improved safety (21). Here we compared survival, weight, and lung histology during a 24-month study period and did not see any differences between F/HN-SIV- and PBS-treated mice. We included only female mice in the study because they can be more readily housed together for prolonged periods of time. It is unlikely that the toxicology profile in male mice would be significantly different. However, before progression into clinical trial a good laboratory practice (GLP)-toxicology study, including male and female animals and dose-ranging, has to be performed. Despite the encouraging toxicology profile of our current vector configuration we plan to assess further modifications before final vector selection for clinical trials, including the use of mammalian promoters and ubiquitous chromatin opening elements. The former have been shown to reduce the risk of insertional mutagenesis compared with strong viral promoters (22), whereas the latter may reduce gene silencing (22). The ability to administer

![Figure 6](image-url)

**Figure 6.** F/HN simian immunodeficiency virus (SIV) transduces primary human pulmonary cells. (A) Microscopic section showing primary human airway epithelial cells obtained from nasal brushings (left, GC = goblet cell, CC = ciliated airway epithelial cell) or human lung slices (right, AW = airway, P = parenchyma). (B) Nasal brushings were transduced with F/HN-SIV-luciferase (Lux) at a multiplicity of infection (MOI) of 25 and 250 or treated with phosphate-buffered saline (PBS) (negative control) and Lux expression was quantified 24 hours after transduction. Each dot represents one sample. Horizontal bars represent the group median. ***$P < 0.005$ when compared with negative controls. (C) Human lung slices were transfected with F/HN-SIV-Lux ($2 \times 10^7$ TU/slice) or remained untransfected (negative control) and Lux expression quantified 2, 7, and 14 days after transduction. Two independent experiments were performed (open and closed symbols). (D) Sheep lung slices were transfected with F/HN-SIV-Lux ($2 \times 10^7$ TU/slice) or remained untransfected (negative control) and Lux expression quantified up to 26 days after transduction. Two independent experiments were performed (open and closed symbols). Each dot represents one animal. Horizontal bars represent the group median. *$P < 0.05$, **$P < 0.01$, ***$P < 0.005$ when compared with negative control. RLU = relative light units.
this vector repeatedly and efficiently also opens the possibility of using nonintegrating lentiviral vectors (23), which may further reduce the genotoxic risk.

As part of our translational pathway we next determined whether F/HN-SIV is able to transduce human tissues. We have previously shown that F/HN-SIV can transduce fully differentiated human ALI cultures when analyzed 5 days after transduction (11). These cultures mimic human airway epithelium and are difficult to transfect (24). Here, we have extended these studies and show that F/HN-SIV–mediated expression in ALIs is stable; persists for at least 3 months (the length of the experiment); and is higher than GL67A–mediated expression, which in our hands is currently the most efficient nonviral vector. Preliminary experiments indicated that in contrast to lipid-mediated gene transfer, F/HN-SIV does not seem to damage the ALI cultures, but more extensive studies are required to determine acute toxicity in vitro and in vivo.

To further evaluate the viral vector in even more relevant tissues we assessed freshly obtained human primary airway cells and showed that F/HN-SIV-Lux transduction leads to significant levels of luciferase expression. We performed only short-term (24 h) experiments to avoid potential cell division, which would have affected interpretation of the results. Collection of primary cells by nasal brushing exposes the basolateral membrane of these cells and we cannot exclude the possibility that the vector may have entered the cells by this route. However, experiments performed in mice in vivo and in ALI cultures clearly show that F/HN-SIV can transduce airway epithelial cells when applied to the apical membrane without the need to coadminister agents to open tight junctions. There was no difference in gene expression when cells were transduced with an MOI of 25 or 250. In future experiments the MOI will be further reduced to determine the minimum MOI for efficient transduction.

We also assessed F/HN-SIV in precision-cut human lung slices. Expression in both experiments was stable and persisted for at least 14 days, after which the experiment was terminated because of reduced tissue viability. Although we have not determined which cells express the recombinant protein these studies show that persistent SIV–mediated transduction into human pulmonary cells is feasible and is not prevented by viral restriction factors. We also transduced ovine lung slices, which are generally more resilient when cultured (Nikki Newman, personal communication); stable luciferase expression was detectable for at least 26 days. These data support the future use of these models in the clinical development of this vector.

SeV shares high sequence homology with human parainfluenza virus and preexisting immunity may be a factor. Interestingly, Slobod and coworkers (25) assessed SeV-vaccination against human parainfluenza virus and reported evidence of immunogenicity in three of nine vaccines despite preexisting, cross-reactive immunity presumably induced by previous exposure to human parainfluenza virus-1. Although this initial study is encouraging, the effects of preexisting humoral immunity on virus transduction efficiency is something we will address as a high priority.

Gene transfer to the airway epithelium is more difficult than originally anticipated. Until now viral gene transfer agents have not been useful for the treatment of chronic lung disease, such as CF, because of immunogenicity, which prevents successful repeat administration. Lentivirus-based vectors are a notable exception. Moving novel therapies to the clinic requires that relevant evidence for safety and efficacy is gathered in appropriate models. Here, we begin to place this vector onto a translational pathway to the clinic and provide a body of supportive evidence for F/HN-pseudotyped SIV as a potential gene transfer agent for CF including (1) lifetime gene expression and efficient repeat administration in mouse lung, (2) lack of chronic toxicity, and (3) persistent gene expression in human ex vivo models.

The data presented here support F/HN-SIV as a promising vector for pulmonary gene therapy, with potential for many diseases including CF. We are currently undertaking the next critical steps (vector optimization and virus production) in this developmental process toward clinical evaluation and are improving vector optimization and viral production methods to support progression into early phase trials.

Author disclosures are available with the text of this article at www.atjjournals.org.

Acknowledgment: The authors thank Lucinda Hellings and Samia Soussı for help with preparing the manuscript.

References


